Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Neuphoria Therapeutics Inc. (NEUP) had Return on Tangible Equity of -28.92% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-4.90M |
|
-- |
|
-- |
|
$6.70M |
|
$-6.70M |
|
$0.59M |
|
$-4.94M |
|
$-4.94M |
|
$-4.90M |
|
$-4.90M |
|
$-4.90M |
|
$-4.90M |
|
$-5.53M |
|
$-6.53M |
|
4.40M |
|
4.40M |
|
$1.03 |
|
$2.21 |
|
| Balance Sheet Financials | |
$21.07M |
|
-- |
|
$7.64M |
|
$28.71M |
|
$0.76M |
|
-- |
|
$3.35M |
|
$4.11M |
|
$24.60M |
|
$16.96M |
|
$24.60M |
|
5.41M |
|
| Cash Flow Statement Financials | |
$-12.35M |
|
-- |
|
$17.92M |
|
$14.29M |
|
$19.87M |
|
$5.58M |
|
$0.35M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
27.85 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.35M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-19.94% |
|
|
Return on Tangible Equity |
-28.92% |
-17.08% |
|
-19.94% |
|
$4.55 |
|
$-2.81 |
|
$-2.81 |
|